Breaking News Instant updates and real-time market news.

ICPT

Intercept

$98.12

-15.36 (-13.54%)

08:18
09/13/17
09/13
08:18
09/13/17
08:18

Intercept should be bought on weakness, says BMO Capital

BMO Capital analyst M. Ian Somaiya says the letter sent by Intercept to healthcare providers regarding its Ocaliva drug relates to failure by doctors to adhere to dose adjustments recommended in its label. Since no new adverse events were cited in the letter, the analyst does not expect any changes to the label. He continues to expect strong Ocaliva prescriptions to result in the company reporting beat and raise Q3 results, and he recommends buying the stock on weakness. He keeps a $221 price target and an Outperform rating on the stock.

ICPT Intercept
$98.12

-15.36 (-13.54%)

09/12/17
JEFF
09/12/17
NO CHANGE
JEFF
Intercept selloff an 'overreaction,' says Jefferies
Jefferies analyst Michael Yee said the sell off in Intercept shares is an "overreaction" to the "Dear Healthcare Provider Letter" and said the risk/benefit of OCA remains favorable. The analyst said there is no change to his Buy thesis and $275 price target and would be buyers of the stock and expects shares to recover as the Phase III trial in cirrhotic patients is initiated by year-end and as we approach Phase III NASH results in early 2019.
09/12/17
BARD
09/12/17
NO CHANGE
Target $332
BARD
Outperform
Baird would buy Intercept on weakness
Baird analyst Brian Skorney recommends buying Intercept shares on weakness related to the "Dear Healthcare Provider Letter." The analyst said there is no new information in the letter and serves as a reminder to modify does according to the label for patients with hepatic impairment following cases of Ocaliva being dosed more frequently than recommended. Skorny rates Intercept an Outperform with a $332 price target.
09/13/17
SBSH
09/13/17
NO CHANGE
Target $150
SBSH
Buy
Intercept price target lowered to $150 from $240 at Citi
Citi analyst Joel Beatty lowered his price target for Intercept Pharmaceuticals to $150 saying a "more robust" competitive landscape in both primary biliary cholangitis and nonalcoholic steatohepatitis could limit peak sales of Ocaliva. While the drug appears to be effective and safe in NASH, its overall profile may "not be strong enough to drive a rapid increase" in the NASH diagnosis rate upon approval, limiting the drug's first mover advantage, Beatty tells investors in a research after the company sent a letter to health care providers warning that serious liver injuries, including death, have been reported in primary biliary cholangitis patients dosed with Ocaliva at higher than recommended levels. Safety concerns are likely to remain an overhang on the shares at least until results from the Phase 3 Regenerate trial in the first half of 2019, which is beyond the 12 month time horizon of the new target price, Beatty writes. He keeps a Buy rating on Intercept. The stock yesterday closed down 13.5%, or $15.36, to $98.12.
09/13/17
MSCO
09/13/17
NO CHANGE
MSCO
Underweight
Intercept talks raise concern of potentially larger issue, says Morgan Stanley
Morgan Stanley analyst Andrew Berens noted that Intercept attended the firm's healthcare conference and discussed its recently sent "Dear Healthcare Provider" letter regarding liver toxicity seen with Ocaliva in some PBC patients. Discussion at the event suggests Ocaliva may have direct effect on liver toxicity in the presence of cholestasis and/or high drug levels, according to Berens, who sees this issue having significant implications for the drug, especially in NASH patients, he tells investors. Berens keeps an Underweight rating and $75 price target on Intercept shares, which closed yesterday down 13.5% at $98.12.

TODAY'S FREE FLY STORIES

NQ

NQ Mobile

$3.82

-0.07 (-1.80%)

07:07
01/22/18
01/22
07:07
01/22/18
07:07
Hot Stocks
NQ Mobile proposes to rebrand, change name to "Link Motion Inc." »

NQ Mobile announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

bluebird bio

$175.95

-6.15 (-3.38%)

07:07
01/22/18
01/22
07:07
01/22/18
07:07
Technical Analysis
Technical Take: bluebird bio moves higher »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

OPB

Opus Bank

$28.70

0.05 (0.17%)

07:07
01/22/18
01/22
07:07
01/22/18
07:07
Earnings
Opus Bank reports Q4 EPS including items 3c, consensus 38c »

Reports net income of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

CQH

Cheniere Energy Partners LP

$28.22

0.22 (0.79%)

, CQP

Cheniere Energy Partners

$30.48

0.2 (0.66%)

07:06
01/22/18
01/22
07:06
01/22/18
07:06
Conference/Events
Morgan Stanley to hold a tour »

Annual Morgan Stanley…

CQH

Cheniere Energy Partners LP

$28.22

0.22 (0.79%)

CQP

Cheniere Energy Partners

$30.48

0.2 (0.66%)

ENLC

EnLink Midstream

$18.75

0.25 (1.35%)

ENLK

EnLink Midstream Partners

$17.45

0.37 (2.17%)

EPD

Enterprise Products

$28.66

0.36 (1.27%)

NBLX

Noble Midstream

$55.10

-0.48 (-0.86%)

PAA

Plains All American

$22.49

-0.09 (-0.40%)

SHLX

Shell Midstream

$30.13

-0.03 (-0.10%)

TRGP

Targa Resources

$50.73

0.04 (0.08%)

WES

Western Gas Partners

$52.31

0.34 (0.65%)

WGP

Western Gas Equity

$40.42

0.5 (1.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 23

    Jan

  • 07

    Feb

  • 16

    Feb

  • 20

    Feb

REGN

Regeneron

$371.53

0.25 (0.07%)

, SNY

Sanofi

$44.60

0.09 (0.20%)

07:06
01/22/18
01/22
07:06
01/22/18
07:06
Hot Stocks
Regeneron reports approval of Dupixent in Japan for atopic dermatitis »

Regeneron (REGN)…

REGN

Regeneron

$371.53

0.25 (0.07%)

SNY

Sanofi

$44.60

0.09 (0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 08

    Mar

  • 25

    Mar

  • 02

    May

SLB

Schlumberger

$76.42

0.05 (0.07%)

07:06
01/22/18
01/22
07:06
01/22/18
07:06
Recommendations
Schlumberger analyst commentary  »

Schlumberger price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTNP

Titan Pharmaceuticals

$1.28

0.025 (2.00%)

, BBRX

Braeburn Pharmaceuticals

07:06
01/22/18
01/22
07:06
01/22/18
07:06
Hot Stocks
Titan Pharmaceuticals discussing U.S. Probuphine commercialization with Braeburn »

Titan Pharmaceuticals…

TTNP

Titan Pharmaceuticals

$1.28

0.025 (2.00%)

BBRX

Braeburn Pharmaceuticals

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CC

Chemours

$54.02

2.42 (4.69%)

, MMM

3M

$248.18

2.27 (0.92%)

07:05
01/22/18
01/22
07:05
01/22/18
07:05
Conference/Events
ASHRAE and AHRI to co-host an expo »

The American Society of…

CC

Chemours

$54.02

2.42 (4.69%)

MMM

3M

$248.18

2.27 (0.92%)

ABB

ABB

$28.01

0.03 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 25

    Jan

  • 15

    Feb

07:05
01/22/18
01/22
07:05
01/22/18
07:05
General news
Oil Action: WTI benchmark futures are fractionally lower »

Oil Action: WTI benchmark…

ACBFF

Aurora Cannabis

$10.77

0.302 (2.89%)

07:05
01/22/18
01/22
07:05
01/22/18
07:05
Hot Stocks
CanniMed announces continuation of discussions with Aurora Cannabis »

CanniMed Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATNX

Athenex

$17.33

0.12 (0.70%)

07:04
01/22/18
01/22
07:04
01/22/18
07:04
Hot Stocks
Athenex announces results of first cohort of Phase 1b clinical trial of Oraxol »

Athenex announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEVB

Level Brands

$5.10

-0.0385 (-0.75%)

07:03
01/22/18
01/22
07:03
01/22/18
07:03
Hot Stocks
Level Brands, Kathy Ireland announce extension of Isodiol license agreement »

Kathy Ireland, Chairman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABAX

Abaxis

$61.16

0.35 (0.58%)

07:03
01/22/18
01/22
07:03
01/22/18
07:03
Hot Stocks
Abaxis granted USDA Approval for new VetScan FLEX4 Rapid Test »

Abaxis' new VetScan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

QURE

uniQure

$17.99

-0.01 (-0.06%)

07:03
01/22/18
01/22
07:03
01/22/18
07:03
Hot Stocks
uniQure receives OMPD in EU for AMT-130 »

uniQure announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTX

BioTime

$2.64

-0.02 (-0.75%)

07:02
01/22/18
01/22
07:02
01/22/18
07:02
Hot Stocks
BioTime sees submitting Renevia for CE mark during Q1 »

BioTime expects to submit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVCN

Neovasc

$0.55

0.0313 (6.02%)

07:02
01/22/18
01/22
07:02
01/22/18
07:02
Hot Stocks
Neovasc CEO Alexei Marko to depart, Fred Colen to succeed »

Neovasc announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBS

CBS

$57.75

-2.25 (-3.75%)

, VIA

Viacom

$39.20

-0.5 (-1.26%)

07:01
01/22/18
01/22
07:01
01/22/18
07:01
Downgrade
CBS, Viacom, Viacom rating change  »

CBS downgraded on higher…

CBS

CBS

$57.75

-2.25 (-3.75%)

VIA

Viacom

$39.20

-0.5 (-1.26%)

VIAB

Viacom

$33.36

-0.59 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

  • 08

    Feb

  • 15

    Feb

AER

AerCap

$54.11

0.38 (0.71%)

07:01
01/22/18
01/22
07:01
01/22/18
07:01
Hot Stocks
AerCap leased, purchased and sold 402 aircraft in 2017 »

AerCap Holdings has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

07:01
01/22/18
01/22
07:01
01/22/18
07:01
Hot Stocks
Bristol-Myers Yervoy expanded indication approved by EC »

Bristol-Myers announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 05

    Feb

  • 08

    Feb

  • 05

    Mar

  • 08

    Mar

LRCX

Lam Research

$207.53

2.08 (1.01%)

, TSM

TSMC

$44.67

0.1 (0.22%)

07:00
01/22/18
01/22
07:00
01/22/18
07:00
Recommendations
Lam Research, TSMC, Ichor Holdings analyst commentary  »

Lam Research price target…

LRCX

Lam Research

$207.53

2.08 (1.01%)

TSM

TSMC

$44.67

0.1 (0.22%)

ICHR

Ichor Holdings

$32.39

-0.36 (-1.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 07

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

07:00
01/22/18
01/22
07:00
01/22/18
07:00
Recommendations
Apple analyst commentary  »

Wells Fargo maintains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

MB

Mindbody

$34.35

1.35 (4.09%)

06:59
01/22/18
01/22
06:59
01/22/18
06:59
Recommendations
Mindbody analyst commentary  »

Mindbody price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 26

    Feb

WMT

Walmart

$104.59

0.29 (0.28%)

, GS

Goldman Sachs

$256.12

5.15 (2.05%)

06:58
01/22/18
01/22
06:58
01/22/18
06:58
Periodicals
Wal-Mart shops Brazil unit stake to Advent, other funds, Reuters reports »

Wal-Mart Stores is in…

WMT

Walmart

$104.59

0.29 (0.28%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 20

    Feb

HAL

Halliburton

$53.01

0.65 (1.24%)

06:54
01/22/18
01/22
06:54
01/22/18
06:54
Hot Stocks
Halliburton continues to experience delays in collecting payments in Venezuela »

Management said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

JNPR

Juniper

$27.85

0.19 (0.69%)

, AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

06:54
01/22/18
01/22
06:54
01/22/18
06:54
Upgrade
Juniper, Amazon.com rating change  »

Oppenheimer calls Amazon…

JNPR

Juniper

$27.85

0.19 (0.69%)

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 01

    Feb

  • 18

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.